nodes	percent_of_prediction	percent_of_DWPC	metapath
Buprenorphine—UGT1A9—Irinotecan—pancreatic cancer	0.0555	0.0763	CbGbCtD
Buprenorphine—CYP2A6—Tamoxifen—pancreatic cancer	0.0351	0.0483	CbGbCtD
Buprenorphine—ABCG2—Tamoxifen—pancreatic cancer	0.0325	0.0447	CbGbCtD
Buprenorphine—ABCG2—Erlotinib—pancreatic cancer	0.0276	0.038	CbGbCtD
Buprenorphine—CYP2A6—Fluorouracil—pancreatic cancer	0.0259	0.0356	CbGbCtD
Buprenorphine—ABCG2—Irinotecan—pancreatic cancer	0.025	0.0343	CbGbCtD
Buprenorphine—CYP3A7—Tamoxifen—pancreatic cancer	0.024	0.033	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Tamoxifen—pancreatic cancer	0.024	0.033	CbGbCtD
Buprenorphine—ABCG2—Fluorouracil—pancreatic cancer	0.024	0.033	CbGbCtD
Buprenorphine—CYP3A7—Irinotecan—pancreatic cancer	0.0184	0.0254	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Irinotecan—pancreatic cancer	0.0184	0.0254	CbGbCtD
Buprenorphine—ABCG2—Docetaxel—pancreatic cancer	0.0183	0.0252	CbGbCtD
Buprenorphine—ABCG2—Sunitinib—pancreatic cancer	0.0182	0.025	CbGbCtD
Buprenorphine—CYP3A5—Tamoxifen—pancreatic cancer	0.018	0.0248	CbGbCtD
Buprenorphine—CYP2C8—Tamoxifen—pancreatic cancer	0.0173	0.0238	CbGbCtD
Buprenorphine—CYP1A2—Dacarbazine—pancreatic cancer	0.0169	0.0232	CbGbCtD
Buprenorphine—CYP3A5—Erlotinib—pancreatic cancer	0.0153	0.0211	CbGbCtD
Buprenorphine—CYP2C8—Erlotinib—pancreatic cancer	0.0147	0.0203	CbGbCtD
Buprenorphine—CYP2C19—Tamoxifen—pancreatic cancer	0.0145	0.02	CbGbCtD
Buprenorphine—CYP3A5—Irinotecan—pancreatic cancer	0.0138	0.019	CbGbCtD
Buprenorphine—ABCG2—Doxorubicin—pancreatic cancer	0.0136	0.0188	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Docetaxel—pancreatic cancer	0.0135	0.0186	CbGbCtD
Buprenorphine—CYP3A7—Docetaxel—pancreatic cancer	0.0135	0.0186	CbGbCtD
Buprenorphine—CYP3A7—Sunitinib—pancreatic cancer	0.0135	0.0185	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Sunitinib—pancreatic cancer	0.0135	0.0185	CbGbCtD
Buprenorphine—CYP1A2—Tamoxifen—pancreatic cancer	0.0134	0.0184	CbGbCtD
Buprenorphine—CYP2C8—Fluorouracil—pancreatic cancer	0.0128	0.0176	CbGbCtD
Buprenorphine—CYP2C9—Tamoxifen—pancreatic cancer	0.0121	0.0166	CbGbCtD
Buprenorphine—ABCB1—Tamoxifen—pancreatic cancer	0.0117	0.0161	CbGbCtD
Buprenorphine—CYP1A2—Erlotinib—pancreatic cancer	0.0114	0.0157	CbGbCtD
Buprenorphine—CYP2D6—Tamoxifen—pancreatic cancer	0.011	0.0152	CbGbCtD
Buprenorphine—CYP3A5—Docetaxel—pancreatic cancer	0.0101	0.0139	CbGbCtD
Buprenorphine—ABCB1—Gemcitabine—pancreatic cancer	0.0101	0.0139	CbGbCtD
Buprenorphine—CYP3A5—Sunitinib—pancreatic cancer	0.0101	0.0139	CbGbCtD
Buprenorphine—ABCB1—Erlotinib—pancreatic cancer	0.00997	0.0137	CbGbCtD
Buprenorphine—CYP1A2—Fluorouracil—pancreatic cancer	0.00988	0.0136	CbGbCtD
Buprenorphine—CYP2D6—Erlotinib—pancreatic cancer	0.00939	0.0129	CbGbCtD
Buprenorphine—ABCB1—Irinotecan—pancreatic cancer	0.009	0.0124	CbGbCtD
Buprenorphine—CYP2C9—Fluorouracil—pancreatic cancer	0.0089	0.0122	CbGbCtD
Buprenorphine—CYP3A4—Tamoxifen—pancreatic cancer	0.00702	0.00966	CbGbCtD
Buprenorphine—ABCB1—Docetaxel—pancreatic cancer	0.0066	0.00907	CbGbCtD
Buprenorphine—ABCB1—Sunitinib—pancreatic cancer	0.00657	0.00903	CbGbCtD
Buprenorphine—CYP3A4—Erlotinib—pancreatic cancer	0.00597	0.00821	CbGbCtD
Buprenorphine—CYP3A4—Irinotecan—pancreatic cancer	0.00539	0.00742	CbGbCtD
Buprenorphine—ABCB1—Doxorubicin—pancreatic cancer	0.00492	0.00676	CbGbCtD
Buprenorphine—CYP2D6—Doxorubicin—pancreatic cancer	0.00463	0.00637	CbGbCtD
Buprenorphine—CYP3A4—Docetaxel—pancreatic cancer	0.00395	0.00544	CbGbCtD
Buprenorphine—CYP3A4—Sunitinib—pancreatic cancer	0.00393	0.00541	CbGbCtD
Buprenorphine—CYP3A4—Doxorubicin—pancreatic cancer	0.00295	0.00405	CbGbCtD
Buprenorphine—Cough—Docetaxel—pancreatic cancer	0.000121	0.000682	CcSEcCtD
Buprenorphine—Angina pectoris—Doxorubicin—pancreatic cancer	0.000121	0.000682	CcSEcCtD
Buprenorphine—Hypersensitivity—Irinotecan—pancreatic cancer	0.000121	0.00068	CcSEcCtD
Buprenorphine—Convulsion—Docetaxel—pancreatic cancer	0.00012	0.000677	CcSEcCtD
Buprenorphine—Hypertension—Docetaxel—pancreatic cancer	0.00012	0.000675	CcSEcCtD
Buprenorphine—Infestation NOS—Epirubicin—pancreatic cancer	0.00012	0.000675	CcSEcCtD
Buprenorphine—Infestation—Epirubicin—pancreatic cancer	0.00012	0.000675	CcSEcCtD
Buprenorphine—Bronchitis—Doxorubicin—pancreatic cancer	0.000119	0.000673	CcSEcCtD
Buprenorphine—Myalgia—Docetaxel—pancreatic cancer	0.000118	0.000665	CcSEcCtD
Buprenorphine—Chest pain—Docetaxel—pancreatic cancer	0.000118	0.000665	CcSEcCtD
Buprenorphine—Arthralgia—Docetaxel—pancreatic cancer	0.000118	0.000665	CcSEcCtD
Buprenorphine—Nausea—Sunitinib—pancreatic cancer	0.000118	0.000665	CcSEcCtD
Buprenorphine—Asthenia—Irinotecan—pancreatic cancer	0.000117	0.000662	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000117	0.000661	CcSEcCtD
Buprenorphine—Urinary tract infection—Epirubicin—pancreatic cancer	0.000116	0.000656	CcSEcCtD
Buprenorphine—Conjunctivitis—Epirubicin—pancreatic cancer	0.000116	0.000656	CcSEcCtD
Buprenorphine—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000115	0.000651	CcSEcCtD
Buprenorphine—Dry mouth—Docetaxel—pancreatic cancer	0.000115	0.000651	CcSEcCtD
Buprenorphine—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	0.000115	0.000651	CcSEcCtD
Buprenorphine—Sweating—Epirubicin—pancreatic cancer	0.000115	0.000647	CcSEcCtD
Buprenorphine—Asthenia—Gemcitabine—pancreatic cancer	0.000114	0.000645	CcSEcCtD
Buprenorphine—Confusional state—Docetaxel—pancreatic cancer	0.000114	0.000643	CcSEcCtD
Buprenorphine—Hepatobiliary disease—Epirubicin—pancreatic cancer	0.000113	0.000638	CcSEcCtD
Buprenorphine—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000113	0.000638	CcSEcCtD
Buprenorphine—Oedema—Docetaxel—pancreatic cancer	0.000113	0.000638	CcSEcCtD
Buprenorphine—Pruritus—Gemcitabine—pancreatic cancer	0.000113	0.000636	CcSEcCtD
Buprenorphine—Infection—Docetaxel—pancreatic cancer	0.000112	0.000634	CcSEcCtD
Buprenorphine—Weight decreased—Doxorubicin—pancreatic cancer	0.000112	0.000633	CcSEcCtD
Buprenorphine—Sinusitis—Epirubicin—pancreatic cancer	0.000112	0.000633	CcSEcCtD
Buprenorphine—Diarrhoea—Irinotecan—pancreatic cancer	0.000112	0.000631	CcSEcCtD
Buprenorphine—Shock—Docetaxel—pancreatic cancer	0.000111	0.000627	CcSEcCtD
Buprenorphine—Nervous system disorder—Docetaxel—pancreatic cancer	0.000111	0.000625	CcSEcCtD
Buprenorphine—Pruritus—Fluorouracil—pancreatic cancer	0.000111	0.000625	CcSEcCtD
Buprenorphine—Infestation—Doxorubicin—pancreatic cancer	0.000111	0.000624	CcSEcCtD
Buprenorphine—Infestation NOS—Doxorubicin—pancreatic cancer	0.000111	0.000624	CcSEcCtD
Buprenorphine—Tachycardia—Docetaxel—pancreatic cancer	0.00011	0.000622	CcSEcCtD
Buprenorphine—Skin disorder—Docetaxel—pancreatic cancer	0.00011	0.00062	CcSEcCtD
Buprenorphine—Bradycardia—Epirubicin—pancreatic cancer	0.000109	0.000616	CcSEcCtD
Buprenorphine—Diarrhoea—Gemcitabine—pancreatic cancer	0.000109	0.000615	CcSEcCtD
Buprenorphine—Dizziness—Irinotecan—pancreatic cancer	0.000108	0.00061	CcSEcCtD
Buprenorphine—Anorexia—Docetaxel—pancreatic cancer	0.000108	0.000608	CcSEcCtD
Buprenorphine—Rhinitis—Epirubicin—pancreatic cancer	0.000108	0.000607	CcSEcCtD
Buprenorphine—Conjunctivitis—Doxorubicin—pancreatic cancer	0.000108	0.000607	CcSEcCtD
Buprenorphine—Urinary tract infection—Doxorubicin—pancreatic cancer	0.000108	0.000607	CcSEcCtD
Buprenorphine—Diarrhoea—Fluorouracil—pancreatic cancer	0.000107	0.000605	CcSEcCtD
Buprenorphine—Hypoaesthesia—Epirubicin—pancreatic cancer	0.000107	0.000602	CcSEcCtD
Buprenorphine—Pharyngitis—Epirubicin—pancreatic cancer	0.000107	0.000601	CcSEcCtD
Buprenorphine—Sweating—Doxorubicin—pancreatic cancer	0.000106	0.000598	CcSEcCtD
Buprenorphine—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000106	0.000598	CcSEcCtD
Buprenorphine—Oedema peripheral—Epirubicin—pancreatic cancer	0.000106	0.000596	CcSEcCtD
Buprenorphine—Hypotension—Docetaxel—pancreatic cancer	0.000106	0.000596	CcSEcCtD
Buprenorphine—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000106	0.000595	CcSEcCtD
Buprenorphine—Urethral disorder—Epirubicin—pancreatic cancer	0.000105	0.000594	CcSEcCtD
Buprenorphine—Hepatobiliary disease—Doxorubicin—pancreatic cancer	0.000105	0.00059	CcSEcCtD
Buprenorphine—Vomiting—Irinotecan—pancreatic cancer	0.000104	0.000587	CcSEcCtD
Buprenorphine—Sinusitis—Doxorubicin—pancreatic cancer	0.000104	0.000586	CcSEcCtD
Buprenorphine—Dizziness—Fluorouracil—pancreatic cancer	0.000104	0.000584	CcSEcCtD
Buprenorphine—Visual impairment—Epirubicin—pancreatic cancer	0.000103	0.000584	CcSEcCtD
Buprenorphine—Rash—Irinotecan—pancreatic cancer	0.000103	0.000582	CcSEcCtD
Buprenorphine—Dermatitis—Irinotecan—pancreatic cancer	0.000103	0.000581	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000103	0.000581	CcSEcCtD
Buprenorphine—Headache—Irinotecan—pancreatic cancer	0.000103	0.000578	CcSEcCtD
Buprenorphine—Insomnia—Docetaxel—pancreatic cancer	0.000102	0.000577	CcSEcCtD
Buprenorphine—Paraesthesia—Docetaxel—pancreatic cancer	0.000102	0.000573	CcSEcCtD
Buprenorphine—Vomiting—Gemcitabine—pancreatic cancer	0.000101	0.000571	CcSEcCtD
Buprenorphine—Bradycardia—Doxorubicin—pancreatic cancer	0.000101	0.00057	CcSEcCtD
Buprenorphine—Dyspnoea—Docetaxel—pancreatic cancer	0.000101	0.000569	CcSEcCtD
Buprenorphine—Somnolence—Docetaxel—pancreatic cancer	0.000101	0.000567	CcSEcCtD
Buprenorphine—Rash—Gemcitabine—pancreatic cancer	0.000101	0.000567	CcSEcCtD
Buprenorphine—Dermatitis—Gemcitabine—pancreatic cancer	0.0001	0.000566	CcSEcCtD
Buprenorphine—Eye disorder—Epirubicin—pancreatic cancer	0.0001	0.000566	CcSEcCtD
Buprenorphine—Tinnitus—Epirubicin—pancreatic cancer	0.0001	0.000565	CcSEcCtD
Buprenorphine—Headache—Gemcitabine—pancreatic cancer	9.99e-05	0.000563	CcSEcCtD
Buprenorphine—Cardiac disorder—Epirubicin—pancreatic cancer	9.97e-05	0.000562	CcSEcCtD
Buprenorphine—Flushing—Epirubicin—pancreatic cancer	9.97e-05	0.000562	CcSEcCtD
Buprenorphine—Vomiting—Fluorouracil—pancreatic cancer	9.97e-05	0.000562	CcSEcCtD
Buprenorphine—Rhinitis—Doxorubicin—pancreatic cancer	9.96e-05	0.000562	CcSEcCtD
Buprenorphine—Dyspepsia—Docetaxel—pancreatic cancer	9.96e-05	0.000561	CcSEcCtD
Buprenorphine—Hypoaesthesia—Doxorubicin—pancreatic cancer	9.89e-05	0.000557	CcSEcCtD
Buprenorphine—Rash—Fluorouracil—pancreatic cancer	9.88e-05	0.000557	CcSEcCtD
Buprenorphine—Dermatitis—Fluorouracil—pancreatic cancer	9.87e-05	0.000557	CcSEcCtD
Buprenorphine—Pharyngitis—Doxorubicin—pancreatic cancer	9.86e-05	0.000556	CcSEcCtD
Buprenorphine—Decreased appetite—Docetaxel—pancreatic cancer	9.83e-05	0.000554	CcSEcCtD
Buprenorphine—Headache—Fluorouracil—pancreatic cancer	9.82e-05	0.000554	CcSEcCtD
Buprenorphine—Urinary tract disorder—Doxorubicin—pancreatic cancer	9.81e-05	0.000553	CcSEcCtD
Buprenorphine—Oedema peripheral—Doxorubicin—pancreatic cancer	9.79e-05	0.000552	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Docetaxel—pancreatic cancer	9.77e-05	0.000551	CcSEcCtD
Buprenorphine—Connective tissue disorder—Doxorubicin—pancreatic cancer	9.76e-05	0.000551	CcSEcCtD
Buprenorphine—Fatigue—Docetaxel—pancreatic cancer	9.75e-05	0.00055	CcSEcCtD
Buprenorphine—Angiopathy—Epirubicin—pancreatic cancer	9.74e-05	0.000549	CcSEcCtD
Buprenorphine—Urethral disorder—Doxorubicin—pancreatic cancer	9.74e-05	0.000549	CcSEcCtD
Buprenorphine—Nausea—Irinotecan—pancreatic cancer	9.72e-05	0.000548	CcSEcCtD
Buprenorphine—Immune system disorder—Epirubicin—pancreatic cancer	9.7e-05	0.000547	CcSEcCtD
Buprenorphine—Mediastinal disorder—Epirubicin—pancreatic cancer	9.68e-05	0.000546	CcSEcCtD
Buprenorphine—Pain—Docetaxel—pancreatic cancer	9.67e-05	0.000545	CcSEcCtD
Buprenorphine—Constipation—Docetaxel—pancreatic cancer	9.67e-05	0.000545	CcSEcCtD
Buprenorphine—Chills—Epirubicin—pancreatic cancer	9.64e-05	0.000543	CcSEcCtD
Buprenorphine—Visual impairment—Doxorubicin—pancreatic cancer	9.58e-05	0.00054	CcSEcCtD
Buprenorphine—Nausea—Gemcitabine—pancreatic cancer	9.47e-05	0.000534	CcSEcCtD
Buprenorphine—Mental disorder—Epirubicin—pancreatic cancer	9.41e-05	0.00053	CcSEcCtD
Buprenorphine—Erythema—Epirubicin—pancreatic cancer	9.35e-05	0.000527	CcSEcCtD
Buprenorphine—Malnutrition—Epirubicin—pancreatic cancer	9.35e-05	0.000527	CcSEcCtD
Buprenorphine—Feeling abnormal—Docetaxel—pancreatic cancer	9.32e-05	0.000526	CcSEcCtD
Buprenorphine—Nausea—Fluorouracil—pancreatic cancer	9.31e-05	0.000525	CcSEcCtD
Buprenorphine—Eye disorder—Doxorubicin—pancreatic cancer	9.29e-05	0.000524	CcSEcCtD
Buprenorphine—Tinnitus—Doxorubicin—pancreatic cancer	9.27e-05	0.000522	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Docetaxel—pancreatic cancer	9.25e-05	0.000522	CcSEcCtD
Buprenorphine—Cardiac disorder—Doxorubicin—pancreatic cancer	9.22e-05	0.00052	CcSEcCtD
Buprenorphine—Flushing—Doxorubicin—pancreatic cancer	9.22e-05	0.00052	CcSEcCtD
Buprenorphine—Flatulence—Epirubicin—pancreatic cancer	9.21e-05	0.000519	CcSEcCtD
Buprenorphine—Tension—Epirubicin—pancreatic cancer	9.17e-05	0.000517	CcSEcCtD
Buprenorphine—Dysgeusia—Epirubicin—pancreatic cancer	9.16e-05	0.000516	CcSEcCtD
Buprenorphine—Nervousness—Epirubicin—pancreatic cancer	9.08e-05	0.000512	CcSEcCtD
Buprenorphine—Back pain—Epirubicin—pancreatic cancer	9.04e-05	0.00051	CcSEcCtD
Buprenorphine—Angiopathy—Doxorubicin—pancreatic cancer	9.02e-05	0.000508	CcSEcCtD
Buprenorphine—Muscle spasms—Epirubicin—pancreatic cancer	8.99e-05	0.000507	CcSEcCtD
Buprenorphine—Immune system disorder—Doxorubicin—pancreatic cancer	8.98e-05	0.000506	CcSEcCtD
Buprenorphine—Mediastinal disorder—Doxorubicin—pancreatic cancer	8.96e-05	0.000505	CcSEcCtD
Buprenorphine—Body temperature increased—Docetaxel—pancreatic cancer	8.94e-05	0.000504	CcSEcCtD
Buprenorphine—Abdominal pain—Docetaxel—pancreatic cancer	8.94e-05	0.000504	CcSEcCtD
Buprenorphine—Chills—Doxorubicin—pancreatic cancer	8.92e-05	0.000503	CcSEcCtD
Buprenorphine—Vision blurred—Epirubicin—pancreatic cancer	8.81e-05	0.000497	CcSEcCtD
Buprenorphine—Mental disorder—Doxorubicin—pancreatic cancer	8.71e-05	0.000491	CcSEcCtD
Buprenorphine—Ill-defined disorder—Epirubicin—pancreatic cancer	8.67e-05	0.000489	CcSEcCtD
Buprenorphine—Erythema—Doxorubicin—pancreatic cancer	8.65e-05	0.000488	CcSEcCtD
Buprenorphine—Malnutrition—Doxorubicin—pancreatic cancer	8.65e-05	0.000488	CcSEcCtD
Buprenorphine—Agitation—Epirubicin—pancreatic cancer	8.59e-05	0.000484	CcSEcCtD
Buprenorphine—Flatulence—Doxorubicin—pancreatic cancer	8.52e-05	0.000481	CcSEcCtD
Buprenorphine—Tension—Doxorubicin—pancreatic cancer	8.49e-05	0.000479	CcSEcCtD
Buprenorphine—Dysgeusia—Doxorubicin—pancreatic cancer	8.47e-05	0.000478	CcSEcCtD
Buprenorphine—Malaise—Epirubicin—pancreatic cancer	8.43e-05	0.000475	CcSEcCtD
Buprenorphine—Nervousness—Doxorubicin—pancreatic cancer	8.4e-05	0.000474	CcSEcCtD
Buprenorphine—Vertigo—Epirubicin—pancreatic cancer	8.4e-05	0.000474	CcSEcCtD
Buprenorphine—Syncope—Epirubicin—pancreatic cancer	8.38e-05	0.000473	CcSEcCtD
Buprenorphine—Back pain—Doxorubicin—pancreatic cancer	8.37e-05	0.000472	CcSEcCtD
Buprenorphine—Hypersensitivity—Docetaxel—pancreatic cancer	8.33e-05	0.00047	CcSEcCtD
Buprenorphine—Muscle spasms—Doxorubicin—pancreatic cancer	8.32e-05	0.000469	CcSEcCtD
Buprenorphine—Palpitations—Epirubicin—pancreatic cancer	8.26e-05	0.000466	CcSEcCtD
Buprenorphine—Loss of consciousness—Epirubicin—pancreatic cancer	8.22e-05	0.000463	CcSEcCtD
Buprenorphine—Cough—Epirubicin—pancreatic cancer	8.16e-05	0.00046	CcSEcCtD
Buprenorphine—Vision blurred—Doxorubicin—pancreatic cancer	8.15e-05	0.00046	CcSEcCtD
Buprenorphine—Asthenia—Docetaxel—pancreatic cancer	8.12e-05	0.000458	CcSEcCtD
Buprenorphine—Convulsion—Epirubicin—pancreatic cancer	8.1e-05	0.000457	CcSEcCtD
Buprenorphine—Hypertension—Epirubicin—pancreatic cancer	8.07e-05	0.000455	CcSEcCtD
Buprenorphine—Ill-defined disorder—Doxorubicin—pancreatic cancer	8.03e-05	0.000453	CcSEcCtD
Buprenorphine—Pruritus—Docetaxel—pancreatic cancer	8e-05	0.000451	CcSEcCtD
Buprenorphine—Myalgia—Epirubicin—pancreatic cancer	7.96e-05	0.000449	CcSEcCtD
Buprenorphine—Arthralgia—Epirubicin—pancreatic cancer	7.96e-05	0.000449	CcSEcCtD
Buprenorphine—Chest pain—Epirubicin—pancreatic cancer	7.96e-05	0.000449	CcSEcCtD
Buprenorphine—Agitation—Doxorubicin—pancreatic cancer	7.95e-05	0.000448	CcSEcCtD
Buprenorphine—Anxiety—Epirubicin—pancreatic cancer	7.93e-05	0.000447	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	7.9e-05	0.000446	CcSEcCtD
Buprenorphine—Discomfort—Epirubicin—pancreatic cancer	7.86e-05	0.000443	CcSEcCtD
Buprenorphine—Malaise—Doxorubicin—pancreatic cancer	7.8e-05	0.00044	CcSEcCtD
Buprenorphine—Dry mouth—Epirubicin—pancreatic cancer	7.78e-05	0.000439	CcSEcCtD
Buprenorphine—Vertigo—Doxorubicin—pancreatic cancer	7.77e-05	0.000438	CcSEcCtD
Buprenorphine—Syncope—Doxorubicin—pancreatic cancer	7.76e-05	0.000437	CcSEcCtD
Buprenorphine—Diarrhoea—Docetaxel—pancreatic cancer	7.74e-05	0.000436	CcSEcCtD
Buprenorphine—Confusional state—Epirubicin—pancreatic cancer	7.69e-05	0.000434	CcSEcCtD
Buprenorphine—Palpitations—Doxorubicin—pancreatic cancer	7.64e-05	0.000431	CcSEcCtD
Buprenorphine—Anaphylactic shock—Epirubicin—pancreatic cancer	7.63e-05	0.00043	CcSEcCtD
Buprenorphine—Oedema—Epirubicin—pancreatic cancer	7.63e-05	0.00043	CcSEcCtD
Buprenorphine—Loss of consciousness—Doxorubicin—pancreatic cancer	7.6e-05	0.000429	CcSEcCtD
Buprenorphine—Infection—Epirubicin—pancreatic cancer	7.58e-05	0.000427	CcSEcCtD
Buprenorphine—Cough—Doxorubicin—pancreatic cancer	7.55e-05	0.000426	CcSEcCtD
Buprenorphine—Shock—Epirubicin—pancreatic cancer	7.51e-05	0.000423	CcSEcCtD
Buprenorphine—Convulsion—Doxorubicin—pancreatic cancer	7.49e-05	0.000423	CcSEcCtD
Buprenorphine—Nervous system disorder—Epirubicin—pancreatic cancer	7.48e-05	0.000422	CcSEcCtD
Buprenorphine—Dizziness—Docetaxel—pancreatic cancer	7.48e-05	0.000422	CcSEcCtD
Buprenorphine—Hypertension—Doxorubicin—pancreatic cancer	7.47e-05	0.000421	CcSEcCtD
Buprenorphine—Tachycardia—Epirubicin—pancreatic cancer	7.45e-05	0.00042	CcSEcCtD
Buprenorphine—Skin disorder—Epirubicin—pancreatic cancer	7.41e-05	0.000418	CcSEcCtD
Buprenorphine—Hyperhidrosis—Epirubicin—pancreatic cancer	7.38e-05	0.000416	CcSEcCtD
Buprenorphine—Chest pain—Doxorubicin—pancreatic cancer	7.36e-05	0.000415	CcSEcCtD
Buprenorphine—Myalgia—Doxorubicin—pancreatic cancer	7.36e-05	0.000415	CcSEcCtD
Buprenorphine—Arthralgia—Doxorubicin—pancreatic cancer	7.36e-05	0.000415	CcSEcCtD
Buprenorphine—Anxiety—Doxorubicin—pancreatic cancer	7.34e-05	0.000414	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	7.31e-05	0.000412	CcSEcCtD
Buprenorphine—Discomfort—Doxorubicin—pancreatic cancer	7.28e-05	0.00041	CcSEcCtD
Buprenorphine—Anorexia—Epirubicin—pancreatic cancer	7.27e-05	0.00041	CcSEcCtD
Buprenorphine—Dry mouth—Doxorubicin—pancreatic cancer	7.2e-05	0.000406	CcSEcCtD
Buprenorphine—Vomiting—Docetaxel—pancreatic cancer	7.19e-05	0.000406	CcSEcCtD
Buprenorphine—Rash—Docetaxel—pancreatic cancer	7.13e-05	0.000402	CcSEcCtD
Buprenorphine—Hypotension—Epirubicin—pancreatic cancer	7.13e-05	0.000402	CcSEcCtD
Buprenorphine—Dermatitis—Docetaxel—pancreatic cancer	7.13e-05	0.000402	CcSEcCtD
Buprenorphine—Confusional state—Doxorubicin—pancreatic cancer	7.12e-05	0.000401	CcSEcCtD
Buprenorphine—Headache—Docetaxel—pancreatic cancer	7.09e-05	0.0004	CcSEcCtD
Buprenorphine—Oedema—Doxorubicin—pancreatic cancer	7.06e-05	0.000398	CcSEcCtD
Buprenorphine—Anaphylactic shock—Doxorubicin—pancreatic cancer	7.06e-05	0.000398	CcSEcCtD
Buprenorphine—Infection—Doxorubicin—pancreatic cancer	7.01e-05	0.000395	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	6.95e-05	0.000392	CcSEcCtD
Buprenorphine—Shock—Doxorubicin—pancreatic cancer	6.95e-05	0.000392	CcSEcCtD
Buprenorphine—Nervous system disorder—Doxorubicin—pancreatic cancer	6.92e-05	0.00039	CcSEcCtD
Buprenorphine—Insomnia—Epirubicin—pancreatic cancer	6.9e-05	0.000389	CcSEcCtD
Buprenorphine—Tachycardia—Doxorubicin—pancreatic cancer	6.89e-05	0.000388	CcSEcCtD
Buprenorphine—Skin disorder—Doxorubicin—pancreatic cancer	6.86e-05	0.000387	CcSEcCtD
Buprenorphine—Paraesthesia—Epirubicin—pancreatic cancer	6.85e-05	0.000386	CcSEcCtD
Buprenorphine—Hyperhidrosis—Doxorubicin—pancreatic cancer	6.82e-05	0.000385	CcSEcCtD
Buprenorphine—Dyspnoea—Epirubicin—pancreatic cancer	6.8e-05	0.000384	CcSEcCtD
Buprenorphine—Somnolence—Epirubicin—pancreatic cancer	6.78e-05	0.000382	CcSEcCtD
Buprenorphine—Anorexia—Doxorubicin—pancreatic cancer	6.73e-05	0.000379	CcSEcCtD
Buprenorphine—Nausea—Docetaxel—pancreatic cancer	6.72e-05	0.000379	CcSEcCtD
Buprenorphine—Dyspepsia—Epirubicin—pancreatic cancer	6.72e-05	0.000379	CcSEcCtD
Buprenorphine—Decreased appetite—Epirubicin—pancreatic cancer	6.63e-05	0.000374	CcSEcCtD
Buprenorphine—Hypotension—Doxorubicin—pancreatic cancer	6.6e-05	0.000372	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Epirubicin—pancreatic cancer	6.59e-05	0.000371	CcSEcCtD
Buprenorphine—Fatigue—Epirubicin—pancreatic cancer	6.58e-05	0.000371	CcSEcCtD
Buprenorphine—Pain—Epirubicin—pancreatic cancer	6.52e-05	0.000368	CcSEcCtD
Buprenorphine—Constipation—Epirubicin—pancreatic cancer	6.52e-05	0.000368	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	6.43e-05	0.000363	CcSEcCtD
Buprenorphine—Insomnia—Doxorubicin—pancreatic cancer	6.39e-05	0.00036	CcSEcCtD
Buprenorphine—Paraesthesia—Doxorubicin—pancreatic cancer	6.34e-05	0.000357	CcSEcCtD
Buprenorphine—Dyspnoea—Doxorubicin—pancreatic cancer	6.29e-05	0.000355	CcSEcCtD
Buprenorphine—Feeling abnormal—Epirubicin—pancreatic cancer	6.29e-05	0.000355	CcSEcCtD
Buprenorphine—Somnolence—Doxorubicin—pancreatic cancer	6.28e-05	0.000354	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Epirubicin—pancreatic cancer	6.24e-05	0.000352	CcSEcCtD
Buprenorphine—Dyspepsia—Doxorubicin—pancreatic cancer	6.21e-05	0.00035	CcSEcCtD
Buprenorphine—Decreased appetite—Doxorubicin—pancreatic cancer	6.14e-05	0.000346	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	6.1e-05	0.000344	CcSEcCtD
Buprenorphine—Fatigue—Doxorubicin—pancreatic cancer	6.09e-05	0.000343	CcSEcCtD
Buprenorphine—Urticaria—Epirubicin—pancreatic cancer	6.06e-05	0.000342	CcSEcCtD
Buprenorphine—Constipation—Doxorubicin—pancreatic cancer	6.04e-05	0.00034	CcSEcCtD
Buprenorphine—Pain—Doxorubicin—pancreatic cancer	6.04e-05	0.00034	CcSEcCtD
Buprenorphine—Body temperature increased—Epirubicin—pancreatic cancer	6.03e-05	0.00034	CcSEcCtD
Buprenorphine—Abdominal pain—Epirubicin—pancreatic cancer	6.03e-05	0.00034	CcSEcCtD
Buprenorphine—Feeling abnormal—Doxorubicin—pancreatic cancer	5.82e-05	0.000328	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Doxorubicin—pancreatic cancer	5.77e-05	0.000325	CcSEcCtD
Buprenorphine—Hypersensitivity—Epirubicin—pancreatic cancer	5.62e-05	0.000317	CcSEcCtD
Buprenorphine—Urticaria—Doxorubicin—pancreatic cancer	5.61e-05	0.000316	CcSEcCtD
Buprenorphine—Abdominal pain—Doxorubicin—pancreatic cancer	5.58e-05	0.000315	CcSEcCtD
Buprenorphine—Body temperature increased—Doxorubicin—pancreatic cancer	5.58e-05	0.000315	CcSEcCtD
Buprenorphine—Asthenia—Epirubicin—pancreatic cancer	5.47e-05	0.000309	CcSEcCtD
Buprenorphine—Pruritus—Epirubicin—pancreatic cancer	5.4e-05	0.000304	CcSEcCtD
Buprenorphine—Diarrhoea—Epirubicin—pancreatic cancer	5.22e-05	0.000294	CcSEcCtD
Buprenorphine—Hypersensitivity—Doxorubicin—pancreatic cancer	5.2e-05	0.000293	CcSEcCtD
Buprenorphine—Asthenia—Doxorubicin—pancreatic cancer	5.07e-05	0.000286	CcSEcCtD
Buprenorphine—Dizziness—Epirubicin—pancreatic cancer	5.05e-05	0.000284	CcSEcCtD
Buprenorphine—Pruritus—Doxorubicin—pancreatic cancer	4.99e-05	0.000282	CcSEcCtD
Buprenorphine—Vomiting—Epirubicin—pancreatic cancer	4.85e-05	0.000274	CcSEcCtD
Buprenorphine—Diarrhoea—Doxorubicin—pancreatic cancer	4.83e-05	0.000272	CcSEcCtD
Buprenorphine—Rash—Epirubicin—pancreatic cancer	4.81e-05	0.000271	CcSEcCtD
Buprenorphine—Dermatitis—Epirubicin—pancreatic cancer	4.81e-05	0.000271	CcSEcCtD
Buprenorphine—Headache—Epirubicin—pancreatic cancer	4.78e-05	0.00027	CcSEcCtD
Buprenorphine—Dizziness—Doxorubicin—pancreatic cancer	4.67e-05	0.000263	CcSEcCtD
Buprenorphine—Nausea—Epirubicin—pancreatic cancer	4.53e-05	0.000256	CcSEcCtD
Buprenorphine—Vomiting—Doxorubicin—pancreatic cancer	4.49e-05	0.000253	CcSEcCtD
Buprenorphine—Rash—Doxorubicin—pancreatic cancer	4.45e-05	0.000251	CcSEcCtD
Buprenorphine—Dermatitis—Doxorubicin—pancreatic cancer	4.45e-05	0.000251	CcSEcCtD
Buprenorphine—Headache—Doxorubicin—pancreatic cancer	4.42e-05	0.000249	CcSEcCtD
Buprenorphine—Nausea—Doxorubicin—pancreatic cancer	4.19e-05	0.000236	CcSEcCtD
Buprenorphine—OPRM1—Signaling Pathways—HIF1A—pancreatic cancer	9.22e-06	9.66e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	9.22e-06	9.66e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TSC2—pancreatic cancer	9.2e-06	9.64e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—CD44—pancreatic cancer	9.2e-06	9.63e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	9.06e-06	9.48e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—APOE—pancreatic cancer	9e-06	9.43e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	9e-06	9.43e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	8.92e-06	9.34e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GLP1R—pancreatic cancer	8.85e-06	9.26e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—KDR—pancreatic cancer	8.82e-06	9.24e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—GCG—pancreatic cancer	8.82e-06	9.23e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—EGFR—pancreatic cancer	8.76e-06	9.17e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PIK3CD—pancreatic cancer	8.74e-06	9.15e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—DPYD—pancreatic cancer	8.7e-06	9.11e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—PIK3CA—pancreatic cancer	8.67e-06	9.08e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—APOE—pancreatic cancer	8.49e-06	8.89e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—TYMP—pancreatic cancer	8.47e-06	8.87e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PIK3CD—pancreatic cancer	8.45e-06	8.85e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PIK3CG—pancreatic cancer	8.43e-06	8.83e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	8.41e-06	8.81e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—PIK3CB—pancreatic cancer	8.4e-06	8.8e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—NFKBIA—pancreatic cancer	8.39e-06	8.79e-05	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—PIK3CA—pancreatic cancer	8.37e-06	8.77e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PIK3CG—pancreatic cancer	8.36e-06	8.75e-05	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—PTEN—pancreatic cancer	8.33e-06	8.72e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—NOTCH1—pancreatic cancer	8.31e-06	8.7e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—STK11—pancreatic cancer	8.29e-06	8.68e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—KRAS—pancreatic cancer	8.28e-06	8.67e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—SLC2A2—pancreatic cancer	8.26e-06	8.65e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—TYMS—pancreatic cancer	8.23e-06	8.62e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CD44—pancreatic cancer	8.21e-06	8.6e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	8.17e-06	8.56e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PPARG—pancreatic cancer	8.14e-06	8.52e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PIK3CG—pancreatic cancer	8.13e-06	8.51e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—NRAS—pancreatic cancer	8.13e-06	8.51e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CXCL8—pancreatic cancer	8.07e-06	8.46e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PPARG—pancreatic cancer	8.07e-06	8.45e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	8.04e-06	8.42e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—EGF—pancreatic cancer	8.03e-06	8.41e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—HRAS—pancreatic cancer	8.02e-06	8.4e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CD44—pancreatic cancer	8.01e-06	8.39e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	7.96e-06	8.34e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	7.89e-06	8.26e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—GCG—pancreatic cancer	7.87e-06	8.24e-05	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—AKT1—pancreatic cancer	7.8e-06	8.17e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	7.78e-06	8.15e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CASP3—pancreatic cancer	7.73e-06	8.09e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—GCG—pancreatic cancer	7.68e-06	8.04e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PIK3CG—pancreatic cancer	7.66e-06	8.02e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PIK3CB—pancreatic cancer	7.62e-06	7.98e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—PIK3CA—pancreatic cancer	7.6e-06	7.96e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CD44—pancreatic cancer	7.55e-06	7.91e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PTGS2—pancreatic cancer	7.55e-06	7.9e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CCND1—pancreatic cancer	7.52e-06	7.88e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CD44—pancreatic cancer	7.48e-06	7.84e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CTNNB1—pancreatic cancer	7.45e-06	7.8e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PIK3CD—pancreatic cancer	7.41e-06	7.76e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—EGFR—pancreatic cancer	7.4e-06	7.75e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—STK11—pancreatic cancer	7.4e-06	7.75e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PPARG—pancreatic cancer	7.39e-06	7.74e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PIK3CB—pancreatic cancer	7.37e-06	7.72e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PIK3CD—pancreatic cancer	7.35e-06	7.7e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	7.33e-06	7.67e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MMP9—pancreatic cancer	7.3e-06	7.65e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	7.26e-06	7.6e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—PTEN—pancreatic cancer	7.26e-06	7.6e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GCG—pancreatic cancer	7.24e-06	7.58e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—STK11—pancreatic cancer	7.22e-06	7.56e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	7.18e-06	7.52e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GCG—pancreatic cancer	7.18e-06	7.51e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PIK3CD—pancreatic cancer	7.14e-06	7.48e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—TYMS—pancreatic cancer	7.13e-06	7.47e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—AKT1—pancreatic cancer	7.08e-06	7.42e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CXCL8—pancreatic cancer	7.08e-06	7.41e-05	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—PIK3CA—pancreatic cancer	7.08e-06	7.41e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—HRAS—pancreatic cancer	7.03e-06	7.37e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—KRAS—pancreatic cancer	6.99e-06	7.32e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	6.95e-06	7.27e-05	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—AKT1—pancreatic cancer	6.84e-06	7.16e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GLP1R—pancreatic cancer	6.83e-06	7.15e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—STK11—pancreatic cancer	6.81e-06	7.13e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CASP3—pancreatic cancer	6.78e-06	7.1e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—STK11—pancreatic cancer	6.75e-06	7.07e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PIK3CD—pancreatic cancer	6.74e-06	7.05e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—SRC—pancreatic cancer	6.73e-06	7.05e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—DPYD—pancreatic cancer	6.72e-06	7.03e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—APOE—pancreatic cancer	6.7e-06	7.01e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CCND1—pancreatic cancer	6.6e-06	6.91e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PTEN—pancreatic cancer	6.58e-06	6.89e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—VEGFA—pancreatic cancer	6.56e-06	6.87e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CTNNB1—pancreatic cancer	6.53e-06	6.84e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—STAT3—pancreatic cancer	6.49e-06	6.8e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—NRAS—pancreatic cancer	6.48e-06	6.78e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PIK3CB—pancreatic cancer	6.46e-06	6.77e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—PIK3CA—pancreatic cancer	6.43e-06	6.73e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PIK3CB—pancreatic cancer	6.4e-06	6.71e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MMP9—pancreatic cancer	6.4e-06	6.71e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PTGS2—pancreatic cancer	6.4e-06	6.71e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CD44—pancreatic cancer	6.4e-06	6.7e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	6.37e-06	6.67e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PTEN—pancreatic cancer	6.37e-06	6.67e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—TYMS—pancreatic cancer	6.36e-06	6.67e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PTGS2—pancreatic cancer	6.35e-06	6.65e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	6.33e-06	6.63e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	6.26e-06	6.56e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PIK3CB—pancreatic cancer	6.23e-06	6.52e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—TYMS—pancreatic cancer	6.21e-06	6.51e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—AKT1—pancreatic cancer	6.21e-06	6.5e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	6.21e-06	6.5e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GCG—pancreatic cancer	6.13e-06	6.42e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PIK3CG—pancreatic cancer	6.04e-06	6.33e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MYC—pancreatic cancer	6.03e-06	6.32e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—TGFB1—pancreatic cancer	6.02e-06	6.3e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CXCL8—pancreatic cancer	5.98e-06	6.27e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—HRAS—pancreatic cancer	5.95e-06	6.23e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—SRC—pancreatic cancer	5.9e-06	6.18e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—EGFR—pancreatic cancer	5.9e-06	6.18e-05	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—PIK3CA—pancreatic cancer	5.87e-06	6.15e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PIK3CB—pancreatic cancer	5.87e-06	6.15e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—TYMS—pancreatic cancer	5.85e-06	6.13e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PPARG—pancreatic cancer	5.83e-06	6.11e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PTGS2—pancreatic cancer	5.82e-06	6.09e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—TYMS—pancreatic cancer	5.8e-06	6.08e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—APOE—pancreatic cancer	5.8e-06	6.07e-05	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—AKT1—pancreatic cancer	5.78e-06	6.05e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—STK11—pancreatic cancer	5.76e-06	6.04e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—VEGFA—pancreatic cancer	5.75e-06	6.02e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CASP3—pancreatic cancer	5.73e-06	6e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—STAT3—pancreatic cancer	5.69e-06	5.96e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—NRAS—pancreatic cancer	5.68e-06	5.95e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PTEN—pancreatic cancer	5.58e-06	5.85e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—KRAS—pancreatic cancer	5.58e-06	5.84e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CCND1—pancreatic cancer	5.57e-06	5.84e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PTEN—pancreatic cancer	5.53e-06	5.8e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CTNNB1—pancreatic cancer	5.52e-06	5.78e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	5.49e-06	5.75e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MMP9—pancreatic cancer	5.41e-06	5.67e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	5.41e-06	5.67e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PTEN—pancreatic cancer	5.38e-06	5.64e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PIK3CD—pancreatic cancer	5.31e-06	5.56e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MYC—pancreatic cancer	5.29e-06	5.54e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—TGFB1—pancreatic cancer	5.28e-06	5.53e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—AKT1—pancreatic cancer	5.25e-06	5.5e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PIK3CG—pancreatic cancer	5.23e-06	5.48e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—APOE—pancreatic cancer	5.18e-06	5.42e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—EGFR—pancreatic cancer	5.18e-06	5.42e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—PIK3CA—pancreatic cancer	5.12e-06	5.36e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PTEN—pancreatic cancer	5.07e-06	5.31e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—APOE—pancreatic cancer	5.05e-06	5.29e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PPARG—pancreatic cancer	5.05e-06	5.29e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—SRC—pancreatic cancer	4.99e-06	5.23e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—TYMS—pancreatic cancer	4.96e-06	5.19e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—TP53—pancreatic cancer	4.96e-06	5.19e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CD44—pancreatic cancer	4.94e-06	5.17e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	4.9e-06	5.13e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—KRAS—pancreatic cancer	4.89e-06	5.12e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—VEGFA—pancreatic cancer	4.86e-06	5.09e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—STAT3—pancreatic cancer	4.81e-06	5.04e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—NRAS—pancreatic cancer	4.8e-06	5.03e-05	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—AKT1—pancreatic cancer	4.8e-06	5.02e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—APOE—pancreatic cancer	4.76e-06	4.99e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—HRAS—pancreatic cancer	4.74e-06	4.96e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GCG—pancreatic cancer	4.73e-06	4.96e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—APOE—pancreatic cancer	4.72e-06	4.94e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PIK3CG—pancreatic cancer	4.67e-06	4.89e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PIK3CA—pancreatic cancer	4.64e-06	4.86e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PIK3CB—pancreatic cancer	4.63e-06	4.85e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PIK3CD—pancreatic cancer	4.6e-06	4.82e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PTGS2—pancreatic cancer	4.59e-06	4.8e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PIK3CG—pancreatic cancer	4.56e-06	4.77e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PPARG—pancreatic cancer	4.51e-06	4.72e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PIK3CA—pancreatic cancer	4.49e-06	4.7e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MYC—pancreatic cancer	4.47e-06	4.68e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	4.47e-06	4.68e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TGFB1—pancreatic cancer	4.46e-06	4.67e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—STK11—pancreatic cancer	4.45e-06	4.66e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PPARG—pancreatic cancer	4.4e-06	4.61e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—EGFR—pancreatic cancer	4.37e-06	4.58e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—TP53—pancreatic cancer	4.35e-06	4.55e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	4.3e-06	4.5e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PIK3CG—pancreatic cancer	4.26e-06	4.46e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—AKT1—pancreatic cancer	4.18e-06	4.38e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—HRAS—pancreatic cancer	4.16e-06	4.35e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PPARG—pancreatic cancer	4.15e-06	4.34e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—KRAS—pancreatic cancer	4.13e-06	4.33e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PPARG—pancreatic cancer	4.11e-06	4.31e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PIK3CD—pancreatic cancer	4.11e-06	4.3e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—APOE—pancreatic cancer	4.03e-06	4.22e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PIK3CB—pancreatic cancer	4.01e-06	4.2e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PIK3CD—pancreatic cancer	4.01e-06	4.2e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PTEN—pancreatic cancer	4e-06	4.19e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PTGS2—pancreatic cancer	3.97e-06	4.16e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PIK3CA—pancreatic cancer	3.94e-06	4.13e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PIK3CA—pancreatic cancer	3.9e-06	4.09e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—TYMS—pancreatic cancer	3.83e-06	4.01e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	3.82e-06	4e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PIK3CA—pancreatic cancer	3.8e-06	3.98e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—AKT1—pancreatic cancer	3.79e-06	3.97e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	3.78e-06	3.96e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PIK3CD—pancreatic cancer	3.74e-06	3.92e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TP53—pancreatic cancer	3.67e-06	3.85e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—AKT1—pancreatic cancer	3.67e-06	3.84e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	3.64e-06	3.81e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PIK3CB—pancreatic cancer	3.58e-06	3.75e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PIK3CA—pancreatic cancer	3.58e-06	3.75e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PTGS2—pancreatic cancer	3.55e-06	3.71e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PPARG—pancreatic cancer	3.51e-06	3.68e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—HRAS—pancreatic cancer	3.51e-06	3.68e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PIK3CB—pancreatic cancer	3.49e-06	3.66e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PTEN—pancreatic cancer	3.47e-06	3.63e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PTGS2—pancreatic cancer	3.46e-06	3.63e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	3.29e-06	3.45e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PIK3CB—pancreatic cancer	3.26e-06	3.42e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PTGS2—pancreatic cancer	3.26e-06	3.42e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PTGS2—pancreatic cancer	3.23e-06	3.39e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—AKT1—pancreatic cancer	3.22e-06	3.37e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	3.2e-06	3.35e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—AKT1—pancreatic cancer	3.19e-06	3.34e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—APOE—pancreatic cancer	3.11e-06	3.26e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—AKT1—pancreatic cancer	3.1e-06	3.25e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PTEN—pancreatic cancer	3.09e-06	3.24e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PTEN—pancreatic cancer	3.02e-06	3.16e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—AKT1—pancreatic cancer	2.92e-06	3.06e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PTEN—pancreatic cancer	2.84e-06	2.98e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PIK3CA—pancreatic cancer	2.82e-06	2.96e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PTEN—pancreatic cancer	2.82e-06	2.95e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	2.81e-06	2.94e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	2.79e-06	2.92e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PTGS2—pancreatic cancer	2.76e-06	2.89e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PPARG—pancreatic cancer	2.71e-06	2.84e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	2.47e-06	2.59e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PIK3CA—pancreatic cancer	2.44e-06	2.56e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PTEN—pancreatic cancer	2.41e-06	2.52e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—AKT1—pancreatic cancer	2.31e-06	2.41e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PIK3CA—pancreatic cancer	2.18e-06	2.29e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	2.15e-06	2.25e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PTGS2—pancreatic cancer	2.13e-06	2.23e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PIK3CA—pancreatic cancer	2.13e-06	2.23e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	2.01e-06	2.1e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—AKT1—pancreatic cancer	2e-06	2.09e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PIK3CA—pancreatic cancer	1.99e-06	2.08e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PTEN—pancreatic cancer	1.86e-06	1.95e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—AKT1—pancreatic cancer	1.78e-06	1.87e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—AKT1—pancreatic cancer	1.74e-06	1.82e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	1.7e-06	1.78e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—AKT1—pancreatic cancer	1.64e-06	1.72e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—AKT1—pancreatic cancer	1.63e-06	1.7e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—AKT1—pancreatic cancer	1.39e-06	1.45e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	1.31e-06	1.37e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—AKT1—pancreatic cancer	1.07e-06	1.12e-05	CbGpPWpGaD
